

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Kawakami, et.al.


Group Art Unit: 1642

Serial No. : 09/073,138

Examiner: Huff, S.

Filed : May 5, 1998

For : MELANOMA ANTIGENS AND THEIR USE IN DIAGNOSTIC
AND THERAPEUTIC METHODS



ASSISTANT COMMISSIONER FOR PATENTS
Washington, D.C. 20231

RESPONSE TO OFFICIAL ACTION PURSUANT TO 37 C.F.R. §1.115

Sir:

In response to the Official Action dated November 3, 1998, applicants present the following amendment and remarks.

IN THE CLAIMS

Please amend the claims as follows.

29 (amended) A pharmaceutical composition comprising [an effective amount of] gp100 (SEQ ID NO: 27) or an immunogenic peptide having 5-20 contiguous amino acids within the gp100 sequence and a pharmacologically acceptable excipient, diluent or carrier.

30 (amended) A method of treating melanoma in a mammal comprising administering a pharmaceutical composition comprising gp100 (SEQ ID NO: 27) or an immunogenic peptide having 5-20 contiguous amino acids within the gp100 sequence to said mammal in an effective amount to stimulate the production of immune cells.